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Bile Aspiration for Diagnosis of Candida glabrata
Cholecystitis
Infection with Candida species is a common nosocomial
problem in critically ill patients [1–3]. Candidemia is
associated with a high mortality rate; the clinical outcome
strongly depends on timely application of an appropriate
antifungal [4]. However, even though many antifungals
are available now, clinical and microbiological failures of
antifungal therapy are encountered frequently [3]. Little
evidence exists to guide the management of this difficult
situation. The change of antifungal therapy to an alter-
native agent is often considered. However, failure of
antifungal therapy might also be due to a second fungus
missed at the time of the initial diagnosis. Therefore,
continuous search for an infectious focus should be a pri-
ority. We report the case of a breakthrough infection due
to Candida glabrata in a patient with Candida albicans
candidemia. C. glabrata cholecystitis was diagnosed with
bile aspiration which also at least partially cured the
infectious nidus.
A 76-year-old woman was referred to the ICU of our
hospital with severe C. albicans sepsis. The personal his-
tory of the patient was remarkable for surgical removal of
the bladder because of a carcinoma. Local complications
prompted further operations, including construction of an
ileocoecal reservoir. On day 4 of the hospitalization an
ileum conduit was connected to the reservoir. The post-
operative course was complicated by peritonitis due to a
leaky anastomosis, making an ileostoma necessary on day
20. Because of short bowel syndrome parenteral nutrition
was started. The patient slowly improved over the next
weeks.
On the 11th week of the hospitalization the patient
was transferred to the ICU with dyspnea and delirium.
Computer tomography (CT) of the thorax on day 75
showed pulmonary embolism and infiltrates, prompting
anticoagulation and antibiotic treatment. Two blood cul-
tures (BacTAlert, bioMe´rieux, Marcy l’Etoile, France)
grew C. albicans after 5 days. The tip of the central
catheter also grew C. albicans. CHROMagar Candida
plates (CHROMagar Company, Paris, France) were used
for primary identification. The diagnosis was confirmed
using API Candida (bioMe´rieux). Antifungal therapy with
fluconazole, 400 mg iv once daily, was initiated. Despite
persistently elevated markers for systemic inflammation,
further blood cultures were negative.
On day 90 the CT-scan demonstrated new peribron-
chovascular infiltrates, suggestive of Aspergillus pneu-
monia. The antifungal regiment was changed to
voriconazole, 200 mg iv twice daily. Abdominal com-
plaints prompted a CT-scan of the abdomen on day 95,
demonstrating an enlarged gall bladder with perivesicular
fluid, suggestive of acalculous cholecystitis. On day 97,
150 ml of slightly turbid gall bladder fluid were aspirated.
Semiquantitative cultures grew moderate amounts of C.
glabrata (no bacterial growth was observed). The sus-
ceptibility testing of C. glabrata revealed intermediate
susceptibility to fluconazole (minimal inhibitory concen-
tration, MIC, 16 lg/ml) but susceptibility to voriconazole
(MIC 0.25 lg/ml). On day 111 the patient had substan-
tially improved and was transferred to a peripheral hos-
pital. Within the following weeks, short bowel syndrome
prevented complete recovery. Surgery was attempted to
correct the ileostoma. The patient, however, succumbed
to postoperative septic complications. Blood cultures did
not show resurgence of candidemia.
Candida species account for 2.9% of bloodstream
pathogens in Swiss hospitals [1]. Although Candida spe-
cies are considered to be normal commensal organisms,
disseminated candidiasis is life threatening. Common risk
factors include colonization, broad-spectrum antibiotics, a
central venous catheter, parenteral nutrition, gastrointes-
tinal or cardiac surgery, prolonged hospital or ICU stay,
burns, diabetes mellitus, and immunosuppression [3].
Most of these conditions favor an overgrowth of yeast in
the bowel, provide an entrance route or can be considered
a marker of severe underlying disease. Remarkably, our
patient fulfilled all these risk factors, except no burn
injuries and immunosuppression were present.
The most common Candida species involved is C.
albicans, accounting for 66% of Candida isolates in Swiss
hospitals, followed by C. glabrata (15%) and C. tropicalis
(2–10%) [1]. Our patient has been at high risk for C.
glabrata infection. According to a recent study, certain
Infection 2008; 36: 189–190
DOI 10.1007/s15010-007-7261-y
B. Misselwitz, A. Imhof, M. Schneemann (corresponding author)
Dept. of Medicine, University Hospital Zurich, Raemistrasse 100,
CH-8091, Zürich, Switzerland; Phone: (+41/44) 255-1111, Fax: -4445,
e-mail: markus.schneemann@usz.ch
Received: June 11, 2007 Æ Revision accepted: September 19, 2007
Published online: March 10, 2008
Infection Correspondence
Infection 36 Æ 2008 Æ No. 2  URBAN & VOGEL 189
broad spectrum antibiotics and pretreatment with azole-
antifungal agents favor infection with C. glabrata or
Candida krusei over C. albicans. The risk was strongest
with two of the antibiotics our patient had been exposed
to: piperacillin/tazobactam and vancomycin, which in-
crease the risk by a factor of 4.2 or 6.5, respectively [5].
The differential diagnosis of an enlarged gall bladder
in an ICU patient is challenging. On the one hand, hy-
drops frequently develops in patients who cannot be fed
orally and resolves without specific treatment. On the
other, infectious cholecystitis requires emergent surgical
or percutaneous treatment. In a recent study, commonly
used biochemical or radiological criteria such as ASAT,
ALAT, AP, GGT, gall bladder wall enlargement, or
pericholecystic fluid failed to predict subsequent isolation
of microorganisms in the gall aspirate [6]. Therefore, the
suspicion of infectious cholecystitis largely depends on
clinical judgment. In a patient like ours with sepsis and no
other focus, a suspicious gall bladder should be further
evaluated. In our case, unequivocal microbiological evi-
dence of gall bladder infection has been provided, since C.
glabrata was isolated from the bile aspirate. This is highly
unusual because Candida species are an infrequent gall
bladder pathogen with C. albicans responsible for the
majority of cases and C. glabrata cholecystitis only anec-
dotically reported [7, 8].
The first-line empirical antifungal for candidemia in
hemodynamically stable, non-neutropenic patients and the
first-line treatment of C. albicans is fluconazole. As soon as
species differentiation reveals C. krusei or C. glabrata
fluconazole needs to be replaced, since virtually all C.
krusei and 13–75% of C. glabrata isolates are fluconazole
resistant [3, 9, 10]. The therapeutic options now include
amphothericin B, caspofungin, or voriconazole. While vo-
riconazole is clearly more effective than fluconazole against
C. krusei or C. glabrata, its use against both pathogens re-
mains controversial [2, 3, 11, 12]. For instance, break-
through infections with C. glabrata under voriconazole
prophylaxis were noted; however, the minimal inhibitory
concentration of the isolates has been consistently above
the proposed break point of > 1 lg/ml [13]. In our case the
minimal inhibitory concentration for voriconazole
(0.25 lg/ml) remained well below this break point, making
continued treatment with this drug a reasonable option.
However, even though several potent antifungals are
available, success of antifungal treatment is uncertain.
Therefore, local therapy might be an attractive option. In
our case percutaneous cholecystostomy not only demon-
strated the double yeast infection but also in addition at
least partially cured the local infection. Recently, a study
compared percutaneous cholecystostomy with surgery in
high-risk patients with acute cholecystitis, demonstrating
a low rate of complications [14].
In summary, failure of fluconazole to improve a crit-
ical state in a patient with C. albicans infection raises the
possibility of another Candida species. A search for a
possible focus should be attempted; in our case, aspiration
of an enlarged gallbladder identified C. glabrata and at
least partially cured the infectious focus. Gallbladder
aspiration seems to be a safe and effective option in pa-
tients with suspected biliary candidiasis.
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